This is a multicenter, phase 2, randomized trial to evaluate the efficacy and safety of obinutuzumab with CHOP versus obinutuzumab with bendamustine in treatment-naïve follicular lymphoma (Grade 3A) patients.
Histologically confirmed follicular lymphoma Grades 3A, CD20 positive by immunohistochemistry.
Meets at least one GELF (Groupe d'Etude des Lymphomes Folliculaires) criteria.
No prior systemic treatment for lymphoma.
Presence of measurable lesions.
History of allergy to any component of monoclonal antibodies or investigational drugs.
Central nervous system involvement.
History of previous malignant tumors.
History of active bleeding or bleeding tendencies, or requiring anticoagulant medication.